This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 20% and 6.17%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 46.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -0.85% and 76.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 2.70% and 5.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for scPharmaceuticals, Inc. (SCPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 16.67% and 20.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Recent Price Trend in scPharmaceuticals, Inc. (SCPH) is Your Friend, Here's Why
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
scPharmaceuticals, Inc. (SCPH) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
What Makes scPharmaceuticals, Inc. (SCPH) a New Buy Stock
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 164% Upside in scPharmaceuticals, Inc. (SCPH): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 163.7% in scPharmaceuticals, Inc. (SCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Has scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how scPharmaceuticals, Inc. (SCPH) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval
by Zacks Equity Research
scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.
scPharmaceuticals (SCPH) Plunges on Complete Response Letter
by Zacks Equity Research
scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult patients.
scPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
scPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Hanger (HNGR) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hanger (HNGR) Q3 performance is likely to have benefited from strong demand for Orthotic and Prosthetic services across the board.